Model-informed drug development with hyper accelerated time to submission - exemplified with depemokimab regulatory submissions in interleukin-5-driven diseases"

Speaker(s)

• 

  Jakob Ribbing, PhD (he/him/his)

  Principal Consultant & Client Operations Expert
  Pharmetheus AB

  PDF Slides